Future Of Acadia’s Nuplazid In Alzheimer’s Psychosis Unclear After CRL
An analyst had suggested that in the event of a thumbs-down from the FDA, the company could end up focusing on other catalysts instead.
An analyst had suggested that in the event of a thumbs-down from the FDA, the company could end up focusing on other catalysts instead.